Advertisement

NEXT ARTICLE

[Articles] Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

01:35 EST 10 Feb 2012 | The Lancet

The use of a vaccine targeting PSA that also enhances co-stimulation of the immune system did not seem to exacerbate the immune-related adverse events associated with ipilimumab. Randomised trials are needed to further assess clinical outcomes of the..

Original Article: [Articles] Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

The Lancet

 Channels 215 Associated Channels :: Search

Associated Content for this Article